Oncology Pharma signs letter of intent to acquire stake in Diagnomics, Inc.

globenewswire.com

#SouthKorea #US #funding - Oncology Pharma, Inc. has signed a letter of intent to acquire at least a 50% stake in Diagnomics, Inc., a private CLIA certified & CAP accredited private molecular genomics lab in San Diego.  Included in the acquisition is Diagnomics’ partial of minority stake in EONE-Diagnomics Genome Center in Seoul South Korea. (GlobalNewswire)

Read more...
Linkedin

Want to receive more content like this in your inbox?